Tian Zhang: Best of ASCO Dallas 2024
Best of ASCO, an Official Annual Meeting Review of the American Society of Clinical Oncology (ASCO), is a two-day program designed to provide the latest science and education from the world’s premier oncology event, the ASCO Annual Meeting. This year it was held on July 20-21, Dallas.
Tian Zhang shared updates about ASCO Dallas 2024, on X:
1. Dan Wang one of our UTSW Simmons Cancer Center melanoma experts discusses the NADINA trial at BEST of ASCO Dallas 2024! Stage 3 melanoma best treatment — Neoadjuvnt ipi-nivo and if not great pathologic response, adj switch to dabrafenib/trametinib for BRAF population./Source/
2.We are opening STAR-EV for bladder cancer— EV/radiation then cystectomy for pathologic CR rates — long term goal to improve bladder preservation approaches! Great to have the preclinical data!/Source/
3. Aparna Kamat from MD Anderson Cancer Center with Best of ASCO update on cervical and ovarian cancers! No chemo after chemoXRT for cervical cancer from NRG Oncology trial, interesting trial with ceralasertib and olaparib for ovarian cancer./Source/
4. Thanks The Oncologist for highlighting — important to find MSI high prostate cancer even w BRCA2, MSI-high is driver here — pembro instead of PARPi. Kudos Casey Moore rising UTSW Internal Medicine intern driving this Precision Onc case pub!/Source/
Authors: Casey Moore, Isabel Naraine, Tian Zhang.
Dr. Tian Zhang, an Associate Professor at UT Southwestern Medical Center, specializes in diagnosing and treating genitourinary cancers, including kidney, prostate, bladder, and testicular cancers. She focuses on clinical trials and translational research to develop new therapies and evaluate biomarkers for these malignancies. Dr. Zhang is a member of ASCO, AACR, and ESMO.
